|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim BY, Suh KS, Lee JG, Woo SR, Park IC,
Park SH, Han CJ, Kim SB, Jeong SH, Yeom YI, et al: Integrated
analysis of prognostic gene expression profiles from hepatitis B
virus-positive hepatocellular carcinoma and adjacent liver tissue.
Ann Surg Oncol. 19 Suppl 3:S328–S338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim BY, Choi DW, Woo SR, Park ER, Lee JG,
Kim SH, Koo I, Park SH, Han CJ, Kim SB, et al:
Recurrence-associated pathways in hepatitis B virus-positive
hepatocellular carcinoma. BMC Genomics. 16:2792015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park ER, Kim SB, Lee JS, Kim YH, Lee DH,
Cho EH, Park SH, Han CJ, Kim BY, Choi DW, et al: The mitochondrial
hinge protein, UQCRH, is a novel prognostic factor for
hepatocellular carcinoma. Cancer Med. 6:749–760. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Potelle S, Morelle W, Dulary E, Duvet S,
Vicogne D, Spriet C, Krzewinski-Recchi MA, Morsomme P, Jaeken J,
Matthijs G, et al: Glycosylation abnormalities in Gdt1p/TMEM165
deficient cells result from a defect in Golgi manganese
homeostasis. Hum Mol Genet. 25:1489–1500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosnoblet C, Legrand D, Demaegd D,
Hacine-Gherbi H, de Bettignies G, Bammens R, Borrego C, Duvet S,
Morsomme P, Matthijs G, et al: Impact of disease-causing mutations
on TMEM165 subcellular localization, a recently identified protein
involved in CDG-II. Hum Mol Genet. 22:2914–2928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Foulquier F, Amyere M, Jaeken J, Zeevaert
R, Schollen E, Race V, Bammens R, Morelle W, Rosnoblet C, Legrand
D, et al: TMEM165 deficiency causes a congenital disorder of
glycosylation. Am J Hum Genet. 91:15–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bammens R, Mehta N, Race V, Foulquier F,
Jaeken J, Tiemeyer M, Steet R, Matthijs G and Flanagan-Steet H:
Abnormal cartilage development and altered N-glycosylation in
Tmem165-deficient zebrafish mirrors the phenotypes associated with
TMEM165-CDG. Glycobiology. 25:669–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schulte Althoff S, Grüneberg M, Reunert J,
Park JH, Rust S, Mühlhausen C, Wada Y, Santer R and Marquardt T:
TMEM165 deficiency: Postnatal changes in Glycosylation. JIMD Rep.
26:21–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dulary E, Potelle S, Legrand D and
Foulquier F: TMEM165 deficiencies in Congenital Disorders of
Glycosylation type II (CDG-II): Clues and evidences for roles of
the protein in Golgi functions and ion homeostasis. Tissue Cell.
49:150–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jaeken J, Schachter H, Carchon H, De Cock
P, Coddeville B and Spik G: Carbohydrate deficient glycoprotein
syndrome type II: A deficiency in Golgi localised
N-acetyl-glucosaminyltransferase II. Arch Dis Child. 71:123–127.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peters V, Penzien JM, Reiter G, Körner C,
Hackler R, Assmann B, Fang J, Schaefer JR, Hoffmann GF and
Heidemann PH: Congenital disorder of glycosylation IId (CDG-IId) -
A new entity: Clinical presentation with Dandy-Walker malformation
and myopathy. Neuropediatrics. 33:27–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martinez-Duncker I, Dupré T, Piller V,
Piller F, Candelier JJ, Trichet C, Tchernia G, Oriol R and
Mollicone R: Genetic complementation reveals a novel human
congenital disorder of glycosylation of type II, due to
inactivation of the Golgi CMP-sialic acid transporter. Blood.
105:2671–2676. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Potelle S, Dulary E, Climer L, Duvet S,
Morelle W, Vicogne D, Lebredonchel E, Houdou M, Spriet C,
Krzewinski-Recchi MA, et al: Manganese-induced turnover of TMEM165.
Biochem J. 474:1481–1493. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marrero JA, Romano PR, Nikolaeva O, Steel
L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS and Block
TM: GP73, a resident Golgi glycoprotein, is a novel serum marker
for hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei H, Li B, Zhang R, Hao X, Huang Y, Qiao
Y, Hou J and Li X and Li X: Serum GP73, a marker for evaluating
progression in patients with chronic HBV infections. PLoS One.
8:e538622013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin D, Tao J, Li D, Wang Y, Li L, Hu Z,
Zhou Z, Chang X, Qu C and Zhang H: Golgi protein 73 activation of
MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget.
6:33523–33533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krzewinski-Recchi MA, Potelle S, Mir AM,
Vicogne D, Dulary E, Duvet S, Morelle W, de Bettignies G and
Foulquier F: Evidence for splice transcript variants of TMEM165, a
gene involved in CDG. Biochim Biophys Acta. 1861:737–748. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morelle W, Potelle S, Witters P, Wong S,
Climer L, Lupashin V, Matthijs G, Gadomski T, Jaeken J, Cassiman D,
et al: Galactose supplementation in patients with TMEM165-CDG
rescues the glycosylation defects. J Clin Endocrinol Metab.
102:1375–1386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang
F, Ma Q, Zhou Z, Chen H, Zhang H, et al: mTORC1 up-regulates GP73
to promote proliferation and migration of hepatocellular carcinoma
cells and growth of xenograft tumors in mice. Gastroenterology.
149:741–752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Liu Q, Zhang H, Zhao H, Mao R, Li
Z, Ya S, Jia C and Bao Y: Silencing of GP73 inhibits invasion and
metastasis via suppression of epithelial-mesenchymal transition in
hepatocellular carcinoma. Oncol Rep. 37:1182–1188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma Y, Wang X, Wu Y, Sun B, Lv H, Rong F
and Zheng X: Overexpression of GOLPH3 protein is associated with
worse prognosis in patients with epithelial ovarian cancer. Tumour
Biol. 35:11845–11849. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Q, Ma Y and Xu W: High GOLPH3
expression is associated with poor prognosis and invasion of
hepatocellular carcinoma. Mol Med Rep. 11:4315–4320. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Guo F, Gu M, Wang G, He X, Zhou J,
Peng Y, Wang Z and Wang X: Increased expression of GOLPH3 is
associated with the proliferation of prostate cancer. J Cancer.
6:420–429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taft MH, Behrmann E, Munske-Weidemann LC,
Thiel C, Raunser S and Manstein DJ: Functional characterization of
human myosin-18A and its interaction with F-actin and GOLPH3. J
Biol Chem. 288:30029–30041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schaeffer D, Somarelli JA, Hanna G, Palmer
GM and Garcia-Blanco MA: Cellular migration and invasion uncoupled:
Increased migration is not an inexorable consequence of
epithelial-to-mesenchymal transition. Mol Cell Biol. 34:3486–3499.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pinho SS and Reis CA: Glycosylation in
cancer: Mechanisms and clinical implications. Nat Rev Cancer.
15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
English NM, Lesley JF and Hyman R:
Site-specific de-N-glycosylation of CD44 can activate hyaluronan
binding, and CD44 activation states show distinct threshold
densities for hyaluronan binding. Cancer Res. 58:3736–3742.
1998.PubMed/NCBI
|
|
33
|
Guo HB, Lee I, Kamar M, Akiyama SK and
Pierce M: Aberrant N-glycosylation of beta1 integrin causes reduced
alpha5beta1 integrin clustering and stimulates cell migration.
Cancer Res. 62:6837–6845. 2002.PubMed/NCBI
|
|
34
|
Pinho SS, Seruca R, Gärtner F, Yamaguchi
Y, Gu J, Taniguchi N and Reis CA: Modulation of E-cadherin function
and dysfunction by N-glycosylation. Cell Mol Life Sci.
68:1011–1020. 2011. View Article : Google Scholar : PubMed/NCBI
|
